Description

• X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking including the ability for T-cells to track and destroy cancer cells. Our small molecule drug candidates inhibit C-X-C receptor type 4 (CXCR4), a receptor over-expressed in many cancers. Inhibition of CXCR4 is designed to block non-cancerous immunosuppressive and pro-angiogenic cells from populating the tumor, disrupting the cancer microenvironment and restoring normal immune surveillance functions. We are committed to advancing the field of cancer immunotherapy and immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline. X4P-001, our lead drug candidate, is in Phase 1/2 development for patients with advanced clear cell renal cell carcinoma (ccRCC) and other solid tumors. We are also investigating the use of X4P-001 for the treatment of certain rare primary immunodeficiency diseases. Our second program, X4P-002, is in pre-clinical development for the treatment of brain cancers, including glioblastoma multiforme (GBM). X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA.
• 

  Headquarters:955 Massachusetts Ave , Cambridge, Massachusetts, United States

  More
• 

  Phone Number: +1 857-529-8300

• 

  Website: https://www.x4pharma.com

• 

  Employees:70

• 

  Revenue:$50 - 100M

• 

  Legal Name:X4 Pharmaceuticals

• X4 Pharmaceuticals's Social Media

  
• Is this data correct?

• |  NAICS Code: 325414  |

  Show More